The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study

Background and Aim: Sarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis. Beta-hydroxy-beta-methylbutyrate (HMB) has the potential to increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. The present study ai...

Descripción completa

Detalles Bibliográficos
Autores principales: Lattanzi, Barbara, Bruni, Angelo, Di Cola, Simone, Molfino, Alessio, De Santis, Adriano, Muscaritoli, Maurizio, Merli, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308449/
https://www.ncbi.nlm.nih.gov/pubmed/34371806
http://dx.doi.org/10.3390/nu13072296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308449/
https://www.ncbi.nlm.nih.gov/pubmed/34371806
http://dx.doi.org/10.3390/nu13072296

Ejemplares similares